AR069500A1 - Metodos de tratamiento de la esteatohepatitis no alcoholica (nash ) utilizando productos de cisteamina - Google Patents
Metodos de tratamiento de la esteatohepatitis no alcoholica (nash ) utilizando productos de cisteaminaInfo
- Publication number
- AR069500A1 AR069500A1 ARP080105211A ARP080105211A AR069500A1 AR 069500 A1 AR069500 A1 AR 069500A1 AR P080105211 A ARP080105211 A AR P080105211A AR P080105211 A ARP080105211 A AR P080105211A AR 069500 A1 AR069500 A1 AR 069500A1
- Authority
- AR
- Argentina
- Prior art keywords
- cellulose
- phthalate
- composition
- acetate
- alcoholic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicacion 1: Uso de un producto de cisteamina, para la elaboracion de un medicamento para el tratamiento de un paciente que sufre de enfermedad de hígado graso. Reivindicacion 3: Uso de una composicion que comprende cisteamina o cistamina, o una sal farmacéuticamente aceptable de las mismas, para la elaboracion de un medicamento para el tratamiento de un paciente que sufre de enfermedad de hígado graso no alcoholico (NAFLD) o de esteatohepatitis no alcoholica (NASH). Reivindicacion 12: El uso de la reivindicacion 8, en donde la forma de dosificacion de liberacion retardada o controlada comprende un recubrimiento entérico que libera la composicion de cisteamina cuando la composicion llega al intestino delgado o a una region del tracto gastrointestinal de un sujeto en el cual el pH es mayor a aproximadamente un pH de 4,5. Reivindicacion 13: El uso de la reivindicacion 12, en donde la composicion comprende un recubrimiento seleccionado del grupo integrado por laca, gelatina polimerizada, copolímero de ácido metacrílico tipo C NF, butirato ftalato de celulosa, hidrogeno ftalato de celulosa, propionato ftalato de celulosa, ftalato de polivinil acetato (PVAP), acetato ftalato de celulosa (CAP), acetato trimelitato de celulosa (CAT), ftalato de hidroxipropil metilcelulosa, acetato de hidroxipropil metilcelulosa, succinato de dioxipropil metilcelulosa, carboximetil etilcelulosa (CMEC), acetato succinato de hidroxipropil metilcelulosa (HPMCAS), y polímeros y copolímeros de ácido acrílico, normalmente formados a partir de acrilato de metilo, acrilato de etilo, metacrilato de metilo y/o metacrilato de etilo con copolímeros de ésteres de ácido acrílico y metacrílico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99151707P | 2007-11-30 | 2007-11-30 | |
US8539708P | 2008-07-31 | 2008-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR069500A1 true AR069500A1 (es) | 2010-01-27 |
Family
ID=40679016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080105211A AR069500A1 (es) | 2007-11-30 | 2008-11-28 | Metodos de tratamiento de la esteatohepatitis no alcoholica (nash ) utilizando productos de cisteamina |
Country Status (26)
Country | Link |
---|---|
US (5) | US7994226B2 (es) |
EP (2) | EP2636404B1 (es) |
JP (3) | JP5583022B2 (es) |
KR (1) | KR20100091219A (es) |
CN (2) | CN101932238B (es) |
AR (1) | AR069500A1 (es) |
AU (1) | AU2008329628B2 (es) |
BR (1) | BRPI0819690B8 (es) |
CA (1) | CA2706768C (es) |
CL (1) | CL2008003582A1 (es) |
CY (1) | CY1114126T1 (es) |
DK (1) | DK2214480T3 (es) |
ES (1) | ES2417179T3 (es) |
HK (1) | HK1141945A1 (es) |
HR (1) | HRP20130590T1 (es) |
IL (2) | IL205909B (es) |
MX (2) | MX360827B (es) |
MY (1) | MY156316A (es) |
NZ (1) | NZ585732A (es) |
PL (1) | PL2214480T3 (es) |
PT (1) | PT2214480E (es) |
RU (1) | RU2498795C2 (es) |
SG (1) | SG10201403200RA (es) |
TW (2) | TWI535435B (es) |
WO (1) | WO2009070781A1 (es) |
ZA (1) | ZA201003670B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2535044B1 (en) | 2006-01-27 | 2019-12-18 | The Regents of The University of California | Enterically coated cysteamine bitartrate and cystamine |
AU2008329628B2 (en) | 2007-11-30 | 2014-06-26 | The Regents Of The University Of California | Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products |
CN102892760B (zh) * | 2010-05-19 | 2014-05-07 | 兴和株式会社 | 非醇性脂肪性肝炎的预防和/或治疗剂 |
US20110300190A1 (en) * | 2010-06-08 | 2011-12-08 | Krisani Biosciences (P) Ltd | Compound, composition and uses thereof |
HUE028725T2 (en) * | 2010-07-28 | 2016-12-28 | Orchid Chemicals And Pharmaceuticals Ltd | Diphenyl ether compounds for the treatment of liver and lung diseases, diabetes complications and cardiovascular diseases |
WO2014045293A1 (en) * | 2012-09-24 | 2014-03-27 | Krisani Bioscience (P) Ltd. | Fatty acid amides with a cysteamine or an acetylated cysteamine group and uses thereof |
ES2869884T3 (es) | 2011-09-16 | 2021-10-26 | Galectin Therapeutics Inc | Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y la enfermedad de hígado graso no alcohólico |
BR112014009789A2 (pt) * | 2011-10-26 | 2017-04-25 | Seattle Children's Res Inst | cisteamina no tratamento da doença fibrótica |
CA2851387A1 (en) * | 2011-11-22 | 2013-05-30 | The Regents Of The University Of California | Cysteamine and/or cystamine for treating ischemic injury |
US20150086627A1 (en) * | 2012-03-29 | 2015-03-26 | Halo Therapeutics, Llc. | Dosage forms of halofuginone and methods of use |
US9763974B2 (en) | 2012-06-06 | 2017-09-19 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase |
US20140314841A1 (en) | 2013-04-19 | 2014-10-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases |
AR096628A1 (es) | 2013-06-17 | 2016-01-20 | Raptor Pharmaceuticals Inc | Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella |
US9682123B2 (en) | 2013-12-20 | 2017-06-20 | The Trustees Of Columbia University In The City Of New York | Methods of treating metabolic disease |
CN106659722A (zh) * | 2014-04-18 | 2017-05-10 | 株式会社Lg生命科学 | 用于预防或治疗脂肪肝疾病的组合物 |
TWI781906B (zh) * | 2015-03-03 | 2022-11-01 | 日商興人生命科學股份有限公司 | 麩胱甘肽之用途 |
KR20180034466A (ko) * | 2015-07-02 | 2018-04-04 | 호리즌 오펀 엘엘씨 | Ado-저항성 시스테아민 유사체 및 그의 용도 |
RU2595815C1 (ru) * | 2015-07-13 | 2016-08-27 | федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения Российской Федерации | Способ лечения больных неалкогольным стеатогепатитом на фоне метаболического синдрома |
US10537528B2 (en) | 2015-11-16 | 2020-01-21 | The Regents Of The University Of California | Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds |
US10143665B2 (en) | 2015-11-17 | 2018-12-04 | Horizon Orphan Llc | Methods for storing cysteamine formulations and related methods of treatment |
CN109310653A (zh) | 2016-03-17 | 2019-02-05 | 硫创治疗公司 | 用于控制释放半胱胺和系统治疗半胱胺敏感性病症的组合物 |
ITUA20161799A1 (it) * | 2016-03-18 | 2017-09-18 | Recordati Ind Chimica E Farmaceutica S P A | Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale |
EP3634411B1 (en) * | 2017-06-08 | 2023-09-20 | N-Gene Research Laboratories Inc. | Methods for treating nash and for preventing nash-induced hcc |
US10632092B2 (en) | 2017-08-30 | 2020-04-28 | First Fruits Business Ministry, Llc | Composition for and method to increase serum adiponectin and reduce body fat |
WO2019060634A1 (en) | 2017-09-20 | 2019-03-28 | Thiogenesis Therapeutics, Inc. | METHODS OF TREATING CYSTEAMINE SENSITIVE DISORDERS |
KR102177304B1 (ko) * | 2018-07-23 | 2020-11-10 | 제이투에이치바이오텍 (주) | 비알콜성 지방간염의 예방 또는 치료용 약학 조성물 |
CN111544426A (zh) * | 2019-02-12 | 2020-08-18 | 复旦大学 | 炔丙基半胱氨酸及其在制备新靶点药物中的用途 |
CA3143834A1 (en) * | 2019-07-19 | 2021-01-28 | Xiyan LI | Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy and other uses |
CN111505099B (zh) * | 2020-04-21 | 2023-07-04 | 上海市普陀区中心医院 | Nash的诊断标志物及其应用 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4110441A (en) * | 1974-04-29 | 1978-08-29 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Gamma-l-glutamyl cholamine phosphate |
US4959306A (en) * | 1986-11-28 | 1990-09-25 | Sclavo, Inc. | Labeling design for a binding assay reagent |
US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
US5639743A (en) * | 1992-11-13 | 1997-06-17 | University Of Georgia Research Foundation | Compositions and methods for treating exocrine gland atrophy |
JPH11302178A (ja) * | 1998-02-17 | 1999-11-02 | Otsuka Pharmaceut Factory Inc | 脂肪肝予防及び治療剤 |
US20050059576A1 (en) * | 1998-04-30 | 2005-03-17 | Adamson J. Gordon | Targeted delivery of antiviral compounds through hemoglobin bioconjugates |
CA2236344A1 (en) * | 1998-04-30 | 1999-10-30 | Hemosol Inc. | Hemoglobin-haptoglobin complexes |
US6794414B1 (en) | 1998-06-17 | 2004-09-21 | Yeda Research And Development Co. Ltd. | Method and compositions for treating diseases mediated by transglutaminase activity |
UA73092C2 (uk) * | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
AU2001237080A1 (en) * | 2000-02-14 | 2001-08-20 | Len Booysen | Stabilizer unit |
CN1144585C (zh) * | 2000-12-13 | 2004-04-07 | 华扩达动物科学[I.P.2]有限公司 | 含有半胱胺或其盐类的促进动物快速生长的组合物及用途 |
US7449451B2 (en) * | 2001-08-29 | 2008-11-11 | Premier Micronutrient Corporation | Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks |
GB2379854B (en) | 2001-09-19 | 2006-04-19 | Walcom Animal Science | Dairy cow feed and the use thereof |
WO2003045334A2 (en) * | 2001-11-29 | 2003-06-05 | Sound Pharmaceuticals Incorporated | Methods and compositions for ameliorating the undesirable effects of chemotherapy |
AU2003202219B2 (en) * | 2002-01-04 | 2008-10-23 | Sound Pharmaceuticals Incorporated | Methods for treating hearing loss |
GB2386817B (en) | 2002-02-20 | 2006-08-23 | Walcom Animal Science | Feed for fish and use therof |
JP2004026716A (ja) | 2002-06-25 | 2004-01-29 | Ajinomoto Co Inc | TNFα産生の抑制剤 |
US8017651B2 (en) | 2002-11-22 | 2011-09-13 | Bionexus, Ltd. | Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia |
GB2398497A (en) | 2003-02-19 | 2004-08-25 | Walcom Animal Science | Composition for improving immunity of animals |
WO2005049002A1 (en) | 2003-11-19 | 2005-06-02 | Omega Bio-Pharma International Ltd. | Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers |
WO2005063226A1 (en) | 2003-12-19 | 2005-07-14 | Omega Bio-Pharma (I.P.3) Limited | Compositions and methods for treating diabetes |
US20050209441A1 (en) | 2004-03-22 | 2005-09-22 | Lile Jackson D | Process for promoting proper folding of human serum albumin using a human serum albumin ligand |
CA2565250C (en) | 2004-05-03 | 2013-11-12 | Omega Bio-Pharma (I.P.3) Limited | Cysteamines for treating complications of hypercholesterolemia and diabetes |
KR20070091198A (ko) | 2005-01-05 | 2007-09-07 | 마그드 아메드 코트브 압달라 | 타우린 합성, 생산 및 의약으로서의 용도 |
PL1879599T3 (pl) | 2005-04-20 | 2014-03-31 | Hutchinson Fred Cancer Res | Sposoby, kompozycje i wyroby do zwiększania przeżywalności komórek, tkanek, narządów i organizmów |
BRPI0620255A2 (pt) * | 2005-12-21 | 2011-11-08 | Schering Corp | uso de agentes redutores de colesterol e/ou antagonista/agonista inverso do receptor de h3 |
US20070172514A1 (en) | 2006-01-20 | 2007-07-26 | Francis Chi | Materials and methods for improving livestock productivity |
EP2535044B1 (en) * | 2006-01-27 | 2019-12-18 | The Regents of The University of California | Enterically coated cysteamine bitartrate and cystamine |
WO2007121545A1 (en) * | 2006-04-20 | 2007-11-01 | Universidade Estadual De Campinas-Unicamp | S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions |
AU2007248483A1 (en) | 2006-05-03 | 2007-11-15 | Geisinger Clinic | Methods for diagnosing and predicting non-alcoholic steatohepatitis (NASH) |
WO2008093764A1 (ja) | 2007-02-02 | 2008-08-07 | Kaneka Corporation | 糖尿病予防または治療用組成物 |
AU2008329628B2 (en) * | 2007-11-30 | 2014-06-26 | The Regents Of The University Of California | Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products |
-
2008
- 2008-11-28 AU AU2008329628A patent/AU2008329628B2/en not_active Ceased
- 2008-11-28 MY MYPI2010002498A patent/MY156316A/en unknown
- 2008-11-28 SG SG10201403200RA patent/SG10201403200RA/en unknown
- 2008-11-28 BR BRPI0819690A patent/BRPI0819690B8/pt not_active IP Right Cessation
- 2008-11-28 ES ES08853916T patent/ES2417179T3/es active Active
- 2008-11-28 CN CN200880125923.2A patent/CN101932238B/zh not_active Expired - Fee Related
- 2008-11-28 DK DK08853916.8T patent/DK2214480T3/da active
- 2008-11-28 MX MX2015010032A patent/MX360827B/es unknown
- 2008-11-28 PL PL08853916T patent/PL2214480T3/pl unknown
- 2008-11-28 PT PT88539168T patent/PT2214480E/pt unknown
- 2008-11-28 MX MX2010005921A patent/MX2010005921A/es active IP Right Grant
- 2008-11-28 CN CN201510122652.7A patent/CN104825430B/zh not_active Expired - Fee Related
- 2008-11-28 EP EP13154059.3A patent/EP2636404B1/en not_active Not-in-force
- 2008-11-28 AR ARP080105211A patent/AR069500A1/es unknown
- 2008-11-28 EP EP08853916A patent/EP2214480B1/en active Active
- 2008-11-28 US US12/745,504 patent/US7994226B2/en active Active
- 2008-11-28 NZ NZ585732A patent/NZ585732A/en not_active IP Right Cessation
- 2008-11-28 CA CA2706768A patent/CA2706768C/en not_active Expired - Fee Related
- 2008-11-28 KR KR1020107013228A patent/KR20100091219A/ko not_active Application Discontinuation
- 2008-11-28 TW TW103146662A patent/TWI535435B/zh not_active IP Right Cessation
- 2008-11-28 WO PCT/US2008/085064 patent/WO2009070781A1/en active Application Filing
- 2008-11-28 RU RU2010126631/15A patent/RU2498795C2/ru not_active IP Right Cessation
- 2008-11-28 JP JP2010536206A patent/JP5583022B2/ja active Active
- 2008-11-28 TW TW097146491A patent/TWI478710B/zh not_active IP Right Cessation
- 2008-12-01 CL CL2008003582A patent/CL2008003582A1/es unknown
-
2010
- 2010-05-23 IL IL205909A patent/IL205909B/en active IP Right Grant
- 2010-05-24 ZA ZA2010/03670A patent/ZA201003670B/en unknown
- 2010-09-03 HK HK10108405.0A patent/HK1141945A1/xx not_active IP Right Cessation
-
2011
- 2011-07-15 US US13/183,990 patent/US8263662B2/en active Active
-
2012
- 2012-09-10 US US13/608,134 patent/US9149448B2/en active Active
-
2013
- 2013-06-27 CY CY20131100522T patent/CY1114126T1/el unknown
- 2013-06-27 HR HRP20130590AT patent/HRP20130590T1/hr unknown
-
2014
- 2014-07-17 JP JP2014146814A patent/JP6121951B2/ja active Active
-
2015
- 2015-09-28 US US14/867,386 patent/US9511038B2/en active Active
-
2016
- 2016-11-28 US US15/362,782 patent/US10307386B2/en active Active
-
2017
- 2017-03-30 JP JP2017066622A patent/JP2017165735A/ja active Pending
- 2017-09-19 IL IL254586A patent/IL254586A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR069500A1 (es) | Metodos de tratamiento de la esteatohepatitis no alcoholica (nash ) utilizando productos de cisteamina | |
EA023971B1 (ru) | Применение композиции, содержащей покрытые энтеросолюбильной оболочкой цистамин или цистеамин, для лечения цистиноза и способ лечения цистиноза | |
JP2017128614A5 (es) | ||
CA2868362C (en) | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix | |
JP2013522219A5 (es) | ||
HU9302426D0 (en) | Soft capsule with coating dissoluble in intestines and method for manufacturing it | |
JP2017528431A5 (es) | ||
CA2403670A1 (en) | Multiparticulate drug form comprising at least two differently coated pellet forms | |
JP2018500353A5 (es) | ||
SG10201400685SA (en) | Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia | |
EA201390981A1 (ru) | Разрушающаяся во рту таблетка | |
JP2015506359A5 (es) | ||
RU2014127884A (ru) | Способы лечения сердечно-сосудистого нарушения | |
JP2007530492A5 (es) | ||
CA2797812A1 (en) | Enteric tablet | |
MX356579B (es) | Composicion farmaceutica o nutraceutica de resistencia gastrica con resistencia contra la influenza de etanol. | |
ES2917982T3 (es) | Método para tratar trastornos hepáticos | |
AR071970A1 (es) | Composicion de liberacion pulsatil de sildenafil y proceso para prepararla | |
RU2011110756A (ru) | Фармацевтическая композиция в виде разовой пероральной дозы, содержащая леводопу, карбидопу и энтакапон, или их соли | |
CA2797809A1 (en) | Enteric tablet | |
RU2016115985A (ru) | Лактоферрин для лечения ibd, вызванного бактериальной инвазией | |
CA2733299A1 (en) | Oral pharmaceutical formulation for omeprazole comprising a specific separation layer | |
RU2012139030A (ru) | Вводимая перорально фармацевтическая гранула эпидермального фактора роста | |
WO2009004649A3 (en) | Enteric coated pharmaceutical compositions | |
KR102386018B1 (ko) | 진행된 비알코올성 지방 간염의 치료 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |